Chronic myeloid leukemia (CML) is a hematological disorder characterized by increased
proliferation of the granulocytic cell lineage. We diagnose CML by presence of the …

Objectives and background: The level of early MR is important for the optimization of therapy
and making a decision to a switch to 2nd line therapy in patients (pts) who have not …

To compare the clinical significance of 3-month cytogenetic and molecular monitoring, we
analyzed 1,410 paired cytogenetic and molecular data from 705 chronic-phase chronic …

Abstract Abstract 164 Background: The achievement of a major molecular remission (MMR)
after imatinib therapy in pts with chronic myeloid leukemia (CML) in chronic phase (CP) …

Introduction of tyrosine kinase inhibitors (TKI) dramatically improves the treatment and
survival of the patients with chronic myeloid leukemia (CML) in the last decade. Imatinib (IM) …

Most patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with
tyrosine kinase inhibitors (TKI) achieve complete cytogenetic response (CCyR). An …

Tyrosine kinase inhibitor (TKI) therapy results in deep molecular response (MR) in 60–70%
of chronic myeloid leukemia (CML) patients. However, despite high efficacy of TKIs, many …

Abstract Abstract 745 FN2 Background: Recent studies have shown that treatment of CML-
CP with second generation tyrosine kinase inhibitors (2G-TKI) dasatinib and nilotinib result …

Objectives and background: Introduction of tyrosine kinase inhibitor (TKI) for the treatment of
chronic myeloid leukemia (CML) led to favorable outcome in the majority of patients. About …

Rezumat Introduction. Tyrosine kinase inhibitors (TKIs) discontinuation in patients with
chronic myeloid leukemia (CML) is associated with equivocal outcomes related to the …